Merck&Co. - Orphan Drug Status and FDA Approval Boosted -- New Buy Signal!

Company description

Merck & Company's core businesses include Pharmaceuticals, Vaccines and Animal Health. In the Pharmaceuticals segment, the company develops and markets a variety of medicines for different medical indications, including oncology, immunology, neurology and infectious diseases. These medicines are designed to treat diseases and improve the quality of life of patients.

The Vaccines segment is involved in the research, development and distribution of vaccines for humans. These vaccines are intended to protect against various infectious diseases and are used worldwide.
The Animal Health segment offers products and services for animal health. These include pharmaceutical products, vaccines and health management solutions for both companion animals and livestock.

latest news

Last week, Merck&Co received the important orphan drug status for a treatment for stomach cancer. The FDA approval for the drug KEYTRUDA plus carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer was also announced.

Chart technical outlook

This makes me sit up and take notice of the company. From a technical perspective, Merck&Co is facing an exciting situation. It is about breaking out of the important hurdle of 133 USD, which also marks the current all-time high. Due to the positive news, the share has managed to approach this resistance area today. If a sustained breakout occurs, I expect a further upward movement to the price range of 142/144 USD.

In addition to the blog that is actively maintained here, my information portal Investment.Traders contains other exciting articles, detailed stock analyses, presentations of various investment opportunities and a weekly update in video form. This is my contribution to financial education in Germany.